Theravance Biopharma (TBPH) vs. IntelliPharmaCeutics Intl (IPCI) Head-To-Head Review

IntelliPharmaCeutics Intl (NASDAQ: IPCI) and Theravance Biopharma (NASDAQ:TBPH) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, profitability, risk, analyst recommendations, institutional ownership, dividends and earnings.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for IntelliPharmaCeutics Intl and Theravance Biopharma, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
IntelliPharmaCeutics Intl 0 3 1 0 2.25
Theravance Biopharma 1 0 5 0 2.67

IntelliPharmaCeutics Intl presently has a consensus target price of $2.53, indicating a potential upside of 271.32%. Theravance Biopharma has a consensus target price of $42.83, indicating a potential upside of 53.25%. Given IntelliPharmaCeutics Intl’s higher probable upside, research analysts plainly believe IntelliPharmaCeutics Intl is more favorable than Theravance Biopharma.

Volatility and Risk

IntelliPharmaCeutics Intl has a beta of 1.06, indicating that its stock price is 6% more volatile than the S&P 500. Comparatively, Theravance Biopharma has a beta of 2.09, indicating that its stock price is 109% more volatile than the S&P 500.

Institutional and Insider Ownership

3.3% of IntelliPharmaCeutics Intl shares are owned by institutional investors. Comparatively, 85.8% of Theravance Biopharma shares are owned by institutional investors. 6.1% of Theravance Biopharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Earnings & Valuation

This table compares IntelliPharmaCeutics Intl and Theravance Biopharma’s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
IntelliPharmaCeutics Intl $5.51 million 4.28 -$8.86 million ($0.34) -2.00
Theravance Biopharma $48.65 million 31.08 -$190.66 million ($5.16) -5.42

IntelliPharmaCeutics Intl has higher earnings, but lower revenue than Theravance Biopharma. Theravance Biopharma is trading at a lower price-to-earnings ratio than IntelliPharmaCeutics Intl, indicating that it is currently the more affordable of the two stocks.


This table compares IntelliPharmaCeutics Intl and Theravance Biopharma’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
IntelliPharmaCeutics Intl -160.89% -2,811.75% -119.05%
Theravance Biopharma -1,604.87% -99.43% -47.10%


Theravance Biopharma beats IntelliPharmaCeutics Intl on 9 of the 14 factors compared between the two stocks.

About IntelliPharmaCeutics Intl

Intellipharmaceutics International Inc is a Canada-based pharmaceutical company engaged in the research, development and manufacture of controlled-release and targeted-release oral solid dosage drugs. Its Hypermatrix technology is a multidimensional controlled-release drug delivery platform that is applied to the development of a range of existing and new pharmaceuticals. Based on this technology platform, it has developed various drug delivery systems and a pipeline of products, and product candidates in various stages of development, in therapeutic areas that include neurology and cardiovascular. Its pipeline of products includes Rexista Oxycodone, Regabatin XR, Generic Focalin XR, Generic Effexor XR, Generic Protonix, Generic Glucophage XR, Generic Seroquel XR, Generic Lamictal XR, Generic Keppra XR, Generic Pristiq and Generic Ranexa. Its generic product candidates also include Trazodone hydrochloride extended-release tablets and Carvedilol phosphate extended-release capsules.

About Theravance Biopharma

Theravance Biopharma, Inc. is a biopharmaceutical company. The Company is engaged in creating medicines for patients suffering from serious illness. The Company operates in the segment of discovery (research), development and commercialization of human therapeutics. The Company’s pipeline of internally discovered product candidates includes medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting. Its commercial product VIBATIV (telavancin) is a once-daily dual-mechanism antibiotic approved in the United States and Europe for certain difficult-to-treat infections. Its Revefenacin (TD-4208) is a long-acting muscarinic antagonist (LAMA) being developed as a nebulized treatment for chronic obstructive pulmonary disease. Its neprilysin (NEP) inhibitor program is designed to develop selective NEP inhibitors for the treatment of a range of cardiovascular and renal diseases.

Receive News & Ratings for IntelliPharmaCeutics Intl Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IntelliPharmaCeutics Intl and related companies with's FREE daily email newsletter.

Leave a Reply